Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07024823 · ClinicalTrials.gov registry record · Phase 1

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 in Healthy Participants and Participants With Chronic Kidney Disease and Type 2 Diabetes and to Assess Home Measurements of Creatinine in a Non Interventional Cohort

A Phase 1 study of Chronic Kidney Disease, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 1
Development phase
124
Enrollment target
5
Study locations

NCT07024823 is a Phase 1 study of Chronic Kidney Disease that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 124 participants, below the 3,206-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (96% lower). The trial reports 5 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07024823, a Phase 1 study of Chronic Kidney Disease, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 1
Development phase
124 participants
Enrollment target
5
Study locations

Study Summary

This study will evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses (SAD) and multiple ascending doses (MAD) of AZD4248 administered as an oral solution and intravenous (IV) infusion. Additionally, the study investigates the non-interventional feasibility of home measurement of serum creatinine in participants with diabetic kidney disease (DKD).

Conditions Studied

Chronic Kidney Disease

Interventions

  • DRUG Placebo
  • DRUG AZD4248

Study Locations (5)

California

  • Research Site - Glendale

Illinois

  • Research Site - Chicago

Michigan

  • Research Site - Ann Arbor

Minnesota

  • Research Site - Saint Paul

Texas

  • Research Site - San Antonio

Trial Details

FieldValue
Enrollment Target 124 participants
Start Date 2025-06-09
Est. Completion 2026-06-18
Phase Phase 1

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07024823

The ClinicalTrials.gov registry entry for NCT07024823 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,206-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (96% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Chronic Kidney Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07024823 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, Illinois, Michigan.

Frequently Asked Questions

What is clinical trial NCT07024823 about?

NCT07024823 is a clinical study titled "A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 in Healthy Participants and Participants With Chronic Kidney Disease and Type 2 Diabetes and to Assess Home Measurements of Creatinine in a Non Interventional Cohort". This study will evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses (SAD) and multiple ascending doses (MAD) of AZD4248 administered as an oral solution and intravenous (IV) infusion. Additionally, the study investigates the non-interventional fe...

What is the current status of trial NCT07024823?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 124 participants. The study started on 2025-06-09. Estimated completion is 2026-06-18.

What conditions does trial NCT07024823 study?

This clinical trial studies the following conditions: Chronic Kidney Disease.

What interventions are being tested in trial NCT07024823?

The interventions under investigation include: Placebo (DRUG), AZD4248 (DRUG).

Who is sponsoring clinical trial NCT07024823?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07024823 being conducted?

This trial has 5 study locations across California, Illinois, Michigan, Minnesota, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Kidney Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Chronic Kidney Disease

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.